Literature DB >> 12761613

Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis.

Anne Cornélie J M de Pont, Catherine S C Bouman, Evert de Jonge, Margreeth B Vroom, Harry R Büller, Marcel Levi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12761613     DOI： 10.1007/s00134-003-1781-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

Review 1.  Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.

Authors:  C T Esmon
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 2.  Regulation of blood coagulation.

Authors:  C T Esmon
Journal:  Biochim Biophys Acta       Date:  2000-03-07

3.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.

Authors:  A M Gori; G Pepe; M Attanasio; M Falciani; R Abbate; D Prisco; S Fedi; B Giusti; T Brunelli; B Giusti; T Brunelli; P Comeglio; G F Gensini; G G Neri Serneri
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

5.  Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration.

Authors:  R A Cardigan; H McGloin; I J Mackie; S J Machin; M Singer
Journal:  Kidney Int       Date:  1999-04       Impact factor: 10.612
  5 in total
  8 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

Review 2.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

3.  The effects of continuous venovenous hemofiltration on coagulation activation.

Authors:  Catherine S C Bouman; Anne-Cornélie J M de Pont; Joost C M Meijers; Kamran Bakhtiari; Dorina Roem; Sacha Zeerleder; Gertjan Wolbink; Johanna C Korevaar; Marcel Levi; Evert de Jonge
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 4.  Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis.

Authors:  Anne C J M de Pont; Marcus J Schultz
Journal:  Crit Care       Date:  2009-02-02       Impact factor: 9.097

5.  Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.

Authors:  Luigi Camporota; Eleonora Corno; Eleonora Menaldo; John Smith; Katie Lei; Richard Beale; Duncan Wyncoll
Journal:  Crit Care       Date:  2008-12-18       Impact factor: 9.097

Review 6.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 7.  Recombinant human activated protein C: current insights into its mechanism of action.

Authors:  Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 8.  Practical aspects of treatment with drotrecogin alfa (activated).

Authors:  Luigi Camporota; Duncan Wyncoll
Journal:  Crit Care       Date:  2007       Impact factor: 9.097
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.